Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 16, 2009

Lonza to Manufacture Elusys’ Antianthrax mAb

  • Lonza signed an agreement with Elusys Therapeutics for the manufacture of Anthin™, Elusys’ late -stage mAb against inhaled anthrax. Under terms of the deal, Lonza will provide process development services and manufacture the product using its GS Gene Expression System™.

    Anthin is a humanized, deimmunized mAb that targets the protective antigen of B. anthracis and neutralizes the effects of anthrax toxins. The antibody is being developed for both the prevention and treatment of inhalation anthrax. Elusys has been awarded $34 million from the NIH and DOD for development of the antibody. The product has also been granted fast-track status and orphan drug designation by the FDA. 



Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »